1%吡美莫司乳膏联合红蓝光治疗面部脂溢性皮炎的疗效观察

目的:观察1%吡美莫司乳膏联合红蓝光治疗面部脂溢性皮炎的疗效与安全性。方法:收集2015年4月至2016年4月至我院皮肤科门诊就诊符合脂溢性皮炎诊断标准的患者108例,随机分为两组。治疗组54例采用吡美莫司乳膏联合红蓝光治疗;对照组54例仅采用吡美莫司乳膏治疗。均在治疗6周后进行临床评分判定疗效。结果:治疗结束后,两组治疗前后自身对照比较,差异均有统计学意义(P<0.05)。治疗组治疗后临床症状积分低于对照组(t=-5.16,P<0.05),临床疗效优于对照组(x~2=4.82,P<0.05),差异均具有统计学意义。两组患者均未出现严重不良反应。结论:1%吡美莫司乳膏联合红蓝光联合治疗面部脂溢性皮炎疗效确切,安全性高,在临床上具有一定的推广价值。     

吡美莫司乳膏治疗面部激素依赖性皮炎临床观察

目的观察吡美莫司乳膏治疗面部激素依赖性皮炎的疗效和安全性。方法将69例面部激素依赖皮炎患者随机分为两组,治疗组36例,对照组33例。两组同时口服抗组胺药4周,同时治疗组外用吡美莫司乳膏,对照组外用赋形剂。于治疗1周、4周时观察主观症状和客观体征疗效并记录不良反应。结果治疗组和对照组主观症状1,4周愈显率分别为76.47%和46.88%,91.88%和65.62%,客观症状1,4周愈显率分别为32.35%和9.38%,52.94%和25.00%,差异均具有统计学意义(P均<0.05)。结论吡美莫司乳膏治疗面部激素依赖性皮炎安全有效,且其对主观症状的改善优于对客观体征的改善。     

维胺酯胶囊联合吡美莫司乳膏治疗脂溢性皮炎研究进展

目的 探讨脂溢性皮炎(SD)患者采用维胺酯胶囊联合吡美莫司乳膏治疗对其炎症指标的影响,以为临床治疗提供参考.方法 选择某医院2018年3月至2020年3月的80例SD患者,按随机数字表法分为对照组(n=40)与观察组(n=40).对照组采用维胺酯胶囊治疗,在此基础上,观察组加用吡美莫司乳膏治疗,两组均连续治疗1个月.对...     

1%吡美莫司乳膏治疗面部激素依赖性皮炎疗效观察

目的观察1%吡美莫司乳膏治疗面部激素依赖性皮炎的临床疗效和安全性。方法采用随机、自身对照、开放式的临床试验设计。48例面部激素依赖性皮炎患者,1%吡美莫司乳膏2次/d外涂靶皮损,观察皮损和自觉症状变化并与治疗前对比。结果治疗6周后,48例患者有效率为100%。8例患者出现刺痛和烧灼感,未中断治疗,总体耐受性好,无特殊不良反应。结论 1%吡美莫司乳膏治疗面部激素依赖性皮炎,疗效明显,不良反应少,患者依从性高。     

1%吡美莫司乳膏治疗阴囊湿疹疗效观察

目的探讨1%吡美莫司乳膏治疗阴囊湿疹的疗效及安全性。方法通过随机数字表法将82例患者分为两组,对照组40例,采用百癣夏塔热片治疗,3片/次,3次/d;治疗组42例,在百癣夏塔热片治疗的基础上外用1%吡美莫司乳膏,2次/d,连用21天。结果治疗组第7天、第14天和第21天的有效率分别为45.23%,69.05%和76.19%,优于对照组的37.50%,45.00%和52.50%。两组第14天和第21天的有效率比较差异有统计学意义(P均<0.05)。患者均未出现严重的不良反应。结论 1%吡美莫司乳膏治疗阴囊湿疹有良好的效果,不良反应少。     

派瑞松霜与盐酸特比萘芬乳膏治疗面部脂溢性皮炎的疗效对比

目的 比较派瑞松霜与盐酸特比萘芬乳膏(兰美抒霜)外用治疗面部脂溢性皮炎的疗效。方法 将面部脂溢性皮炎患者随机分为2组：治疗组45例，外用派瑞松霜，对照组42例，外用兰美抒霜，两组均为每日1次，疗程2周。结果 治疗组的痊愈率为68．89％，总有效率为95．56％；对照组的痊愈率为47．62％，总有效率为76．19％。经x^2检验，两组间差异有显著性，派瑞松霜的疗效优于兰美抒霜，未发现派瑞松霜有不良反应。结论 派瑞松霜治疗面部脂溢性皮炎更有效，更安全。     

1%吡美莫司乳膏治疗196例糖皮质激素依赖性皮炎临床分析

目的:分析196例糖皮质激素依赖性皮炎(简称激素依赖性皮炎)患者病因及1%吡美莫司乳膏的疗效。方法:采用问卷调查表的形式记录激素依赖性皮炎患者的临床资料,将符合入选条件的患者随机分为治疗组和对照组,治疗组给予1%吡美莫司乳膏外涂,每日2次,同时给予氯雷他定(开瑞坦)10 mg,每日1次口服;对照组仅给予开瑞坦10 mg,每日1次口服,观察其疗效和不良反应。结果:196例激素依赖性皮炎患者中,男女比为1:4.43,临床分型以面部中央型最为常见(52.55%),在外用的糖皮质激素中,以复方醋酸地塞米松乳膏(皮炎平)最多(39.29%)且多数为患者自行购买。治疗4周后,治疗组有效率(86.21%)高于对照组(25.00%),差异有统计学意义(X~2=5.388,P0.01)。结论:激素依赖性皮炎主要是由于患者缺乏对糖皮质激素制剂正确使用的知识,导致滥用或误用外用糖皮质激素制剂所致。1%吡美莫司乳膏治疗激素依赖性皮炎安全有效。     

依巴斯汀联合1％吡美莫司乳膏治疗面部再发性皮炎疗效观察

笔者2008年1-6月,采用依巴斯汀联合1%吡美莫司乳膏(商品名:爱宁达)治疗面部再发性皮炎40例,取得满意疗效,现报告如下.     

萘替芬酮康唑乳膏治疗面部脂溢性皮炎疗效观察

目的 探讨萘替芬酮康唑乳膏和复方乳酸乳膏混合外涂治疗面部脂溢性皮炎的临床疗效和安全性。方法 将65例面部脂溢性皮炎患者随机分成两组,治疗组33例,将适量萘替芬酮康唑乳膏和复方乳酸乳膏1:1放于洗净的手掌,混合调匀,再均匀涂于面部皮损处;对照组32例,将适量曲安奈德尿素乳膏和复方乳酸乳膏以1:1按上法均匀涂于面部皮损处。疗程均为4周,每2周复诊1次,观察疗效和不良反应。结果 治疗第2,4周后,两组症状总积分均较治疗前显著下降,差异有统计学意义(P<0.05);治疗组有效率分别为72.73%和78.13%,对照组分别为81.82%和87.50%,差异均无统计学意义(P均>0.05)。结论 外涂萘替芬酮康唑乳膏与外涂曲安奈德尿素乳膏治疗面部脂溢性皮炎疗效均满意且相当,但外涂萘替芬酮康唑乳膏更安全,无糖皮质激素乳膏外用的不良反应。     

盐酸左西替利嗪联合吡美莫司乳膏治疗面部糖皮质激素依赖性皮炎疗效观察

我们于2009年10月—2010年10月采用盐酸左西替利嗪(重庆华邦制药股份有限公司)联合1%吡美莫司乳膏(Novartis Pharma Produktions GmbH,Germany)治疗面部糖皮质激素(简称激素)依赖性皮炎30例,取得较好疗效,现报告如下。1资料和方法1.1入选标准①所有患者均符合面部激素依赖性皮炎诊     

羌月乳膏治疗面部脂溢性皮炎的临床观察

目的探讨中药制剂羌月乳膏治疗面部脂溢性皮炎的有效性和安全性。方法将入选的120例面部脂溢性皮炎患者随机分为观察组60例(予羌月乳膏)和对照组60例(予丁苯羟酸软膏),连续局部用药4周。并在治疗结束后随访2周。结果治疗组有效率与对照组差异无统计学意义,在复发率和安全性方面治疗组优于对照组,差异有统计学意义。结论中药制剂羌月乳膏是治疗脂溢性皮炎的安全有效的外用药,而且复发率低,可作为治疗面部脂溢性皮炎的一线用药。     

Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment

Background

Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with low-dose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment.

Objective

The aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD.

Methods

During the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect.

Results

The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well.

Conclusion

The results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.     

曲安奈德益康唑乳膏治疗脂溢性皮炎78例临床观察

目的观察曲安奈德益康唑乳膏治疗微生物相关皮肤病脂溢性皮炎的临床疗效及安全性。方法治疗组78例脂益性皮炎患者,予早、晚各1次外用曲安奈德益康唑乳膏,并轻揉搓片刻,疗程4周。对照组80例予外搽皮炎平,用药方法及疗程同前。每周复诊时观察皮损情况。结果治疗组有效率89．3％,对照组为66．6％;治疗组出现不良反应3例,占3．8％,均予对症处理,与对照组（8例）比较差异有统计学意义（P〈0．05）。结论曲安奈德益康唑乳膏治疗脂溢性皮炎疗效确切,不良反应少。     

姜黄消痤搽剂治疗脂溢性皮炎临床疗效观察

目的探讨姜黄消痤搽剂治疗脂溢性皮炎的疗效。方法治疗组予姜黄消痤搽剂涂患处,对照组外用哈西奈德溶液。两组均早晚各用药1次,疗程为14天,疗程结束时评价疗效;随访2个月观察复发情况。结果治疗组有效率为87.23%,对照组为79.17%,两组比较差异无显著性(P>0.05);治疗组复发率为15.79%,对照组为47.62%,两组比较差异有显著性(P<0.05)。结论姜黄消痤搽剂治疗头皮脂溢性皮炎疗效确切,复发率低。     

1%吡美莫司乳膏联合甲氧沙林治疗白癜风疗效观察

目的观察1%吡美莫司乳膏联合甲氧沙林片治疗白癜风的疗效。方法根据随机数字表法将符合入选标准的90例患者分成两组,各45例,对照组口服甲氧沙林片0.3~0.6mg/(kg.d),每3天1次,服药1.5~2.0h后阳光照射,强度以发生轻度红斑为宜,治疗期间戴墨镜保护眼睛;试验组同时加用1%吡美莫司乳膏,两组均连续治疗3个月。结果试验组和对照组有效率分别为75.6%和37.8%,差异有显著性(P<0.01)。试验组3例皮肤有烧灼感。结论1%吡美莫司乳膏联合甲氧沙林片治疗白癜风临床疗效好。     

Treatment of Oral Lichen Sclerosus with 1% Pimecrolimus Cream

Lichen sclerosus is a chronic inflammatory mucocutaneous disorder predominately affecting prepubertal girls and postmenopausal women. Isolated lichen sclerosus affecting the oral mucosa is exceedingly rare, and only 13 patients with biopsy-proved isolated oral disease have been reported in the literature. We report on a 7-year-old Korean girl with a well-demarcated 1.2×1.2 cm atrophic white plaque with an erythematous border and focal telangiectasia on the left vermillion lip, extending to the labial mucosa. No other cutaneous surfaces, including genitalia, were involved. An incisional biopsy of the plaque on the lip revealed a patchy lichenoid infiltrate of lymphocytes associated with sclerosis of the papillary dermis and a thinned epidermis consistent with a diagnosis of linear orofacial lichen sclerosus. Treatment with a short course of 1% pimecrolimus cream effectively prevented the progression of this lesion.     

Safety, Efficacy, and Dosage of 1% Pimecrolimus Cream for the Treatment of Atopic Dermatitis in Daily Practice

Introduction: Although several controlled clinical trials have demonstrated the efficacy and good tolerability of 1% pimecrolimus cream for the treatment of atopic dermatitis, the results of these trials may not apply to real-life usage. The objective of this study was to evaluate the safety and efficacy of a pimecrolimus-based regimen in daily practice. Methods: This was a 6-month, open-label, multicenter study in 947 patients aged ≥3 months with atopic dermatitis of all severities. The investigators incorporated 1% pimecrolimus cream into patients’ standard treatment protocols on the basis of their clinical diagnosis. Use of topical corticosteroids was allowed at the discretion of the physician. Safety and tolerability were evaluated by monitoring adverse events. Efficacy was evaluated by recording changes in the Investigators’ Global Assessment scores and pruritus scores at each visit. Results: No clinically unexpected adverse events were reported. The discontinuation rate for adverse events was 2.3%. The disease improvement rate was 53.7% at week 1 and 66.9% at week 24. The pimecrolimus-based regimen was particularly effective for the treatment of lesions involving the face (improvement rate: 61.9% at week 1 and 76.7% at week 24). The greatest therapeutic response was experienced by pediatric patients with mild or moderate disease. Nonetheless, 64% and 65% of infants and children, respectively, with severe/very severe facial disease at baseline were clear/almost clear of signs of atopic dermatitis on their face at week 24. In patients aged <18 years, most of the improvement occurred within the first week of treatment, while in adults a progressive improvement was observed over the entire study period. Worsening of disease by the end of the study occurred in 9.5% of patients and was most frequent in adults (12.6%). The discontinuation rate for unsatisfactory therapeutic effect was 4.8%. The mean number of treatment days was 135.6 (SD 53.2). The mean drug consumption (non-US centers only) was 4.2g per treatment day. Drug consumption decreased over time as disease improved. In total, 47% of patients who completed the study never used topical corticosteroids over 6 months. Conclusion: In daily practice, incorporation of 1% pimecrolimus cream into patients’ standard treatment regimen is well tolerated and improves atopic dermatitis in approximately two-thirds of patients. Disease improvement is particularly evident on the face. The greatest therapeutic response is experienced by pediatric patients with mild or moderate disease. In these patients, most of the improvement is observed within 1 week from the start of treatment.     

Twice-daily versus Once-daily Applications of Pimecrolimus Cream 1% for the Prevention of Disease Relapse in Pediatric Patients with Atopic Dermatitis

Abstract:  The aim of this study is to compare twice-daily and once-daily applications of pimecrolimus cream 1% for prevention of atopic dermatitis relapses in pediatric patients. This multicenter trial enrolled 300 outpatients aged 2 to 17 years, with mild-to-severe atopic dermatitis. The patients were initially treated with twice-daily topical pimecrolimus until complete clearance or for up to 6 weeks (open-label period). Those who achieved a decrease of at least 1 point in the Investigator's Global Assessment score were then randomized to double-blind treatment with pimecrolimus cream 1% either twice daily or once daily for up to 16 weeks. Study medication was discontinued during periods of disease remission (Investigator's Global Assessment = 0). The primary efficacy end point of the double-blind phase was disease relapse (worsening requiring topical corticosteroids or additional/alternative therapy and confirmed by Investigator's Global Assessment score ≥ 3 and pruritus score ≥ 2). Of the 300 patients enrolled in the study, 268 were randomized to treatment with pimecrolimus cream 1% either twice daily or once daily ( n  = 134 in each group). The relapse rate was lower in the twice-daily dose group (9.9%) than that in the once-daily dose group (14.7%), but analysis of the time to disease relapse, using a Cox proportional model to adjust for confounding variables, did not show a statistically significant difference between treatment arms (hazard ratio: 0.64; 95% CI: 0.31–1.30). Treatment of active atopic dermatitis lesions with pimecrolimus cream 1% twice daily, followed by the once-daily dosing regimen, was sufficient to prevent subsequent atopic dermatitis relapses over 16 weeks in pediatric patients.     

15%氧化锌乳膏治疗婴儿尿布皮炎40例疗效观察及安全性评价

目的：探讨15%氧化锌乳膏外用治疗尿布皮炎的临床疗效及安全性。方法：80例尿布皮炎患儿,随机分治疗组40例,外用15%氧化锌乳膏,每日2次;对照组40例,外用0.1%丁酸氢化可的松乳膏,每日2次,两组疗程均2周,比较其临床疗效。结果：两组的临床痊愈率、总有效率比较,差异均无统计学意义（均P〉0.05）。结论：15%氧化锌乳膏外用治疗婴儿尿布皮炎疗效肯定,安全性高,可作为临床常规选用外用药之一。